To claim credit for this episode, visit: Mayo Clinic Talks Podcast: Genes & Your Health Guests: Minetta C. Liu, M.D.; Myra J. Wick, M.D., Ph.D. (@MyraWickMD) Host: Denise M. Dupras, M.D., Ph.D. What is cell-free DNA? How does this type of DNA interact with our body? How is it useful in the clinical setting? Advances in technologies has expanded our understanding of cell-free DNA and its implications. Where are we now and what can we look for in the future? Find out these answers and more in the seventh episode of the Genes & Your Health miniseries from the Center for Individualized Medicine. Connect with the Mayo Clinic’s School of Continuous Professional Development online at https://ce.mayo.edu/ or on Twitter @MayoMedEd.

Mayo Clinic Talks

Genes & Your Health Edition - Cell-Free DNA: Implications in Practice

Guest: Paola Sandroni, M.D., Ph.D. Host: Amit K. Ghosh, M.D. (@AmitGhosh006) Syncope is defined as the sudden and transient loss of consciousness and postural tone due to global reduction of blood flow to the reticular activating system. Syncopal episodes are followed by a rapid and spontaneous recovery.  Joining us today is Paola Sandroni, M.D., Ph.D., a neurologist at Mayo Clinic’s Rochester Campus. She will help us sort through the complicated subject of syncope, including its main etiologies and how to distinguish which is affecting your patient. She also outlines the nuances of evidence-based evaluation of syncope, which is largely guided by the patient’s presentation. Additional resources: Thiruganasambandamoorthy V, Kwong K, Wells GA, Sivilotti MLA, Mukarram M, Rowe BH, Lang E, Perry JJ, Sheldon R, Stiell IG, Taljaard M. Development of the Canadian Syncope Risk Score to predict serious adverse events after emergency department assessment of syncope. CMAJ. 2016 Sep 6;188(12):E289-E298. doi: 1503/cmaj.151469. Epub 2016 Jul 4. PMID: 27378464; PMCID: PMC5008955 Connect with the Mayo Clinic’s School of Continuous Professional Development online at https://ce.mayo.edu/ or on Twitter @MayoMedEd.

A Neurologist’s Take on Syncope

To claim credit for this episode, visit: Mayo Clinic Talks Podcast: Genes & Your Health Guests: Stephanie S. Faubion, M.D., M.B.A. (@StephFaubionMD); Kejal Kantarci, M.D. (@KejalKantarciMD); Juliana (Jewel) M. Kling, M.D., M.P.H. (@DrJewelKling) Host: Denise M. Dupras, M.D., Ph.D. Is hormone therapy good or bad for women? What are the myths surrounding it? Is the varying experience of menopause genetic? Join the sixth episode of Mayo Clinic Center for Individualized Medicine’s Genes & Your Health Edition to dive into women’s health and hormones and what you need to know for your practice.   Additional resources: • USPSTF Recommendations Statement for Breast Cancer: Medication Use to Reduce Risk https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/breast-cancer-medications-for-risk-reduction  • Mayo Clinic Center for Individualized Medicine: https://www.mayo.edu/research/centers-programs/center-individualized-medicine  Connect with the Mayo Clinic School of Continuous Professional Development online at https://ce.mayo.edu/ or on Twitter @MayoMedEd. 

Genes & Your Health Edition - Why Does It Matter? Genes, Hormones, and Women’s Health

Guest: Thomas Caulfield, Ph.D. Host: Amit K Ghosh, M.D., MBA (@AmitGhosh006) In this podcast, Dr. Thomas Caulfield from Mayo Clinic Florida describes a novel approach for SARS-CoV2 multi-drug targeting using artificial intelligence. Dr. Caulfield is leading a national team of investigators from Harvard, University of California, In Vivo Biosystems and Mayo Clinic to perform large-scale in silico and in vivo experiments on de novo drugs to better understand COVID-19 and halt its progression.  University of California hosts a live virus BSL3 facility for rapidly screening novel compounds that Dr. Caulfield's lab designs in silico and refines with feedback using machine learning techniques and data layering. Connect with the Mayo Clinic’s School of Continuous Professional Development online at https://ce.mayo.edu/ or on Twitter @MayoMedEd.

Using Artificial Intelligence to Combat COVID-19

To claim credit for this series, visit: Mayo Clinic Talks Podcast: Genes & Your Health Guest: Purna C. Kashyap, M.B.B.S. (@KashyapPurna); Marina R. Walther-Antonio, Ph.D. Host: Denise M. Dupras, M.D., Ph.D. What is the microbiome? How does the microbiome interact with our body? How much of us is nurture, how much is nature? The whole concept of microbiome may be a new idea but have no fear this fifth episode of the Genes & Your Health Edition from the Mayo Clinic Center for Individualized Medicine is here to help answer those questions and more! Additional resources: Mayo Clinic Center for Individualized Medicine: https://www.mayo.edu/research/centers-programs/center-individualized-medicine  Connect with the Mayo Clinic School of Continuous Professional Development online at https://ce.mayo.edu/ or on Twitter @MayoMedEd. 

Genes & Your Health Edition - How Does Your Microbiome Impact Your Health?

This episode is shared from Mayo Clinic Q&A and was recorded in September 29, 2021 Guest:  Gregory A. Poland, M.D. (@drgregpoland) Host: Halena M. Gazelka, M.D. (@hmgazelkamd) The path to approvals for a booster dose of the Pfizer COVID-19 vaccine has seemed complicated.  "This is a confusing set of recommendations," says Dr. Gregory Poland, an infectious diseases expert and head of Mayo Clinic's Vaccine Research Group. "So let's look at the four groups approved for only the Pfizer booster, thus far. If you got a primary series of the Pfizer vaccine, you're 65 and older, and it's been six months or more, you are eligible for a booster. If you're 50–64 and you have medical conditions that place you at high risk, you are eligible for the booster. If you're 18–49, you may be able to get a booster based on a medical condition and if you talk with your health care provider to weigh risks and benefits. And, finally, for people 18–64 years old, who are health care providers in congregate living situations or who have occupations that place them at high risk for transmission, such as school teachers, they also may be eligible. That should happen very soon." In this Mayo Clinic Q&A podcast, Dr. Poland talks more about the approval process for COVID-19 vaccine boosters, including for the Moderna and Johnson & Johnson COVID-19 vaccines. He also discusses the possibility that emergency use approval for children, down to age 5, could come before the end of October. AskMayoExpert COVID-19 Resources: https://askmayoexpert.mayoclinic.org/navigator/COVID-19 Connect with the Mayo Clinic’s School of Continuous Professional Development online at https://ce.mayo.edu/ or on Twitter @MayoMedEd.

Mayo Clinic Q&A: Breaking Down COVID-19 Vaccine Booster Approvals

Guest: Christina A. Dilaveri, M.D. (@CDilaveri) Host: Darryl S. Chutka, M.D. (@ChutkaMD)   Breast cancer is very treatable when detected early. Therefore, early detection becomes very important as it significantly reduces a patient’s risk of developing metastases and death. Breast imaging plays an extremely important role in the detection of early breast cancer, and we now have several modalities of breast imaging available, each with its advantages and disadvantages. Our guest for this podcast is Christina Dilaveri, M.D. a breast disease specialist, from Mayo Clinic’s Rochester Campus. We’ll discuss mammography, ultrasound, MRI, and molecular breast imaging, when they’re indicated, and the advantages of each. You’ll hear which patients should have more than a mammogram and how often it should be performed. Specific topics discussed: The various types of mammography available Indications for breast ultrasound Benefits of breast MRI When breast MRI should be performed Benefits of molecular breast imaging When molecular breast imaging should be performed Connect with the Mayo Clinic School of Continuous Professional Development online at https://ce.mayo.edu/ or on Twitter @MayoMedEd.

Breast Imaging for Patients with Dense Breast Tissue

To claim credit for this series, visit: Mayo Clinic Talks Podcast: Genes & Your Health   Guest: Niloy Jewel J. Samadder, M.D. (@J_Samadder)   Host: Denise M. Dupras, M.D., Ph.D.   Can we find the cause of a patient’s cancer? Is it possible to provide targeted treatment to prevent future cancers by understanding what genetic predispositions a patient or their family members have? In a recently published study, nearly one in six to one in eight cancer patients, depending on which type of cancer they had, carried a genetic predisposition to the development of their cancer. How can we translate these findings into our practice for the benefit of our patients and their families? Tune in to episode four of our Genes & Your Health Edition from the Mayo Clinic Center for Individualized Medicine. Additional resources: Samadder NJ, Riegert-Johnson D, Boardman L, et al. Comparison of universal genetic testing vs guideline-directed targeted testing for patients with hereditary cancer syndrome. JAMA Oncol. 2021;7(2):230–237. doi: 10.1001/jamaoncol.2020.6252 Uson, PLS. Riegert-Johnson, D. Boardman, L. Kisiel, J. et al. Germline cancer susceptibility gene testing in unselected patients with colorectal adenocarcinoma: a multicenter prospective study. Clin Gastroenterol Hepatol. 2021 April 20; doi: 10.1016/j.cgh.2021.04.013 Mayo Clinic’s Center for Individualized Medicine: https://www.mayo.edu/research/centers-programs/center-individualized-medicine  Connect with the Mayo Clinic School of Continuous Professional Development online at https://ce.mayo.edu/ or on Twitter @MayoMedEd.

Genes & Your Health Edition - Genomics and Cancer: Primary Care Impact and Research Advances

Guest: Matthew J. Binnicker, Ph.D. (@DrMattBinnicker) Host: Amit K. Ghosh, M.D. (@AmitGhosh006)   In this podcast Matthew J. Binnicker, Ph.D. discusses the development of different types of testing available to diagnose SARS-CoV2 infection. Binnicker discusses the test characteristics of the rapid antigen tests and RT-PCR test and its variability based on the time when the test was performed. He also discusses the optimal timing of diagnostic testing (rapid testing, RT-PCR) and the role and limitations of antibody testing in COVID-19.   Additional resources: Shah AS, Tande AJ, Challener DW, O’Horo JC, Binnicker MJ, Berbari EF. Diagnostic stewardship: An essential element in a rapidly evolving COVID-19 pandemic. Mayo Clin Proc. 2020;95(9):S17-S19. DOI: https://doi.org/10.1016/j.mayocp.2020.05.039   Connect with the Mayo Clinic School of Continuous Professional Development online at https://ce.mayo.edu/ or on Twitter @MayoMedEd.

The Evolution of COVID-19 Testing

To claim credit for this episode, visit: https://ce.mayo.edu/online-education/content/mayo-clinic-talks-podcast-genes-your-health#group-tabs-node-course-default1 Guest: Jessica A. Wright, Pharm.D., R.Ph. Host: Denise M. Dupras, M.D., Ph.D. Pharmacogenomics helps to identify how your patients’ DNA may affect their response to medications. But there's a lot of different genes! How do we get started? What resources are out there? Do we have to worry about every drug a patient is on? Find out these answers and more in episode three of the Genes & Your Health Edition from the Mayo Clinic Center for Individualized Medicine. Additional resources: PharmGKB: pharmgkb.org Clinical Pharmacogenetics Implementation Consortium (CPIC®): cpicpgx.org Basic Pharmacogenomics Nomenclature: https://www.pharmgkb.org/page/glossary NIH’s National Human Genome Research Institute: Healthcare Provider Resources: https://www.genome.gov/For-Health-Professionals/Provider-Genomics-Education-Resources Mayo Clinic Center for Individualized Medicine: https://www.mayo.edu/research/centers-programs/center-individualized-medicine Connect with the Mayo Clinic School of Continuous Professional Development online at https://ce.mayo.edu/ or on Twitter @MayoMedEd.

Genes & Your Health Edition - Pharmacogenomics and its Value for Primary Care

Guest: David G. Lott, M.D. Host: Amit K. Ghosh, M.D. (@AmitGhosh006) About 60,000 Americans have had their vocal cords removed due to disease or trauma necessitating a laryngectomy. Post-laryngectomy, patients are unable to speak, are at risk for aspiration, and many suffer from significant anguish resulting in depression. Fortunately, there are several treatment options available, the first being laryngeal transplant. While laryngeal transplantation allows patients to smell, taste, swallow, and communicate, it has drawbacks. Currently only a small number of larynx transplants are done in the U.S., and only a select few patients with laryngectomy qualify for larynx transplant. In this episode, Dr. David Lott, division chair of laryngology at Mayo Clinic’s Arizona campus, discusses the role of regenerative medicine, which has shown promise in using 3D printing and a patient’s stem cells in creating a larynx. Connect with the Mayo Clinic School of Continuous Professional Development online at https://ce.mayo.edu/ or on Twitter @MayoMedEd.

Regenerative Techniques for the Larynx

To claim credit for this series, visit: https://ce.mayo.edu/online-education/content/mayo-clinic-talks-podcast-genes-your-health#group-tabs-node-course-default1 Guests: Andrew D. Badley, M.D. (@BadleyAndrew); Matthew J. Binnicker, Ph.D. (@DrMattBinnicker) Host: Denise M. Dupras, M.D., Ph.D. COVID-19. Variants. The future. Does one test fit all?  Will the vaccine continue to provide protection against future variants? What makes the Delta variant more transmissible? Join the second episode of our Genes & Your Health Edition from the Mayo Clinic Center for Individualized Medicine to learn how viral genetics influence transmission, diagnosis, and severity of COVID-19. Additional resources: Mayo Clinic Center for Individualized Medicine: https://www.mayo.edu/research/centers-programs/center-individualized-medicine Connect with the Mayo Clinic School of Continuous Professional Development online at https://ce.mayo.edu/ or on Twitter @MayoMedEd.

Genes & Your Health Edition - How Does Viral Genetics Influence Transmission, Diagnosis, and Severity of COVID-19?

To claim credit for this episode, visit: https://ce.mayo.edu/online-education/content/mayo-clinic-talks-podcast-genes-your-health#group-tabs-node-course-default1 Guests: Matthew J. Ferber, Ph.D. (@Matt_Ferber); Teresa M. Kruisselbrink, M.S., CGC (@T_Kruisselbrink); William C. Palmer, M.D. (@williampalmermd) Host: Denise M. Dupras, M.D., Ph.D. For so long we've heard Genetic Testing is coming. Well guess what, it’s here!  We have over 25 million people who have chosen to participate in direct-to-consumer testing alone. What does this mean for primary care, and does it matter? Find out in the first episode of our Genes & Your Health Edition from the Mayo Clinic Center for Individualized Medicine. Additional resources: TAPESTRY Study: https://www.mayo.edu/research/clinical-trials/cls-20477323?_ga=2.268706548.460922620.1627479724-1519128218.1623079535 Mayo Clinic Center for Individualized Medicine: https://www.mayo.edu/research/centers-programs/center-individualized-medicine Connect with the Mayo Clinic School of Continuous Professional Development online at https://ce.mayo.edu/ or on Twitter @MayoMedEd.

Genes & Your Health Edition - Genomics and Healthcare, Why Does it Matter?

Guest: Elitza S. Theel, Ph.D. (@ElliTheelPhD) Host: Amit K. Ghosh, M.D. (@AmitGhosh006) Dr. Elitza Theel, Professor of Laboratory Medicine and Pathology and Director of Infectious Diseases Serology Laboratory at Mayo Clinic’s Rochester Campus, discusses our immune response to vaccination and natural infection and outlines the different types of antibody assays currently available. Dr. Theel also discusses the concept of herd immunity in the context of different circulating SARS-CoV-2 variants and the increased need to get higher rates of vaccination in the community as the infectivity and transmissibility of circulating SARS-CoV-2 variants changes. We also discuss the status of correlates of protective immunity against SARS-CoV-2 and the need for booster vaccine doses for immunocompromised individuals.  Additional resources: Interim Guidelines for COVID-19 Antibody Testing in Clinical and Public Health Settings https://www.cdc.gov/coronavirus/2019-ncov/lab/resources/antibody-tests-guidelines.html Connect with the Mayo Clinic’s School of Continuous Professional Development online at https://ce.mayo.edu/ or on Twitter @MayoMedEd.

Variants, Virulence, and Vaccines, Oh My!

Guest: Aaron M. Potretzke, M.D. (@potretzke)   Host: Darryl S. Chutka, M.D. (@ChutkaMD)   Microscopic hematuria, and less commonly gross hematuria, are conditions commonly seen by the primary care provider. Malignancy is the most ominous cause of hematuria. Fortunately, other causes are much more likely. Since this is a relatively common health condition, when should we investigate hematuria and what should the evaluation consist of? How do we evaluate a patient’s risk for urinary tract malignancy? Dr. Aaron Potretzke, a urologist at Mayo Clinic joins us to discuss these questions.   Specific topics: Definition of hematuria Benign causes of hematuria Risk of malignancy in low, medium, and high-risk patients Stratifying malignancy risk in patients for genitourinary malignancy Recommended evaluation for patients with hematuria How to manage patients with persistent hematuria despite a negative evaluation Role of urine cytology in the evaluation of hematuria Additional resources: American Urological Association hematuria guideline and algorithm: https://www.auanet.org/guidelines/guidelines/microhematuria Connect with the Mayo Clinic’s School of Continuous Professional Development online at https://ce.mayo.edu/ or on Twitter @MayoMedEd.

Evaluating Hematuria

Stay on top of your primary care practice with podcasts from your colleagues at Mayo Clinic. Curated. Portable. Trusted. Offering continuing medical education - CME - for select episodes. Family medicine, primary care, general internal medicine topics for physicians, nurse practitioners and physician assistants.

hubhopper

Mayo Clinic Talks

hubhopper